Most Read Articles
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.
Roshini Claire Anthony, 5 days ago

Female cancer survivors who undergo fertility preservation before cancer treatment often use their stored gametes/embryos. This highlights the effectiveness of pre-cancer fertility preservation, according to a study presented at ESHRE 2020.

 

Acid suppression therapy plus capecitabine may lower survival in colorectal cancer patients

04 Dec 2019

Concurrent treatment with acid suppression therapy and capecitabine in colorectal cancer patients seems to result in decreased progression-free survival, with a trend towards lower overall survival, according to a study.

Seventy patients participated in this study. After adjusting for disease severity and age, patients on acid suppression therapy at capecitabine initiation (21 percent) had reduced progression-free survival as compared to those not on acid suppression therapy (hazard ratio [HR], 2.24, 95 percent confidence interval [CI], 1.06–4.41; p=0.035).

Use of acid suppression therapy also correlated with a numerical decrease in overall survival (HR, 1.86, 95 percent CI, 0.81–3.91; p=0.14).

A decreased rate of progression-free survival (HR, 6.21, 95 percent CI, 2.56–14.32; p=0.0001) but not overall survival (HR, 1.64, 95 percent CI, 0.68–3.54; p=0.25) was observed in patients on any concomitant acid suppression therapy (25 percent) compared with those without after adjusting for disease severity and age.

“Due to the demonstrated potential of decreased efficacy, concurrent use of proton pump inhibitors or histamine 2 receptor antagonists should be avoided in colorectal cancer patients on treatment with capecitabine monotherapy,” the investigators said.

This single-centre retrospective cohort study included adult patients with colorectal cancer on capecitabine monotherapy between 2011 and 2017. The investigators compared progression-free survival and overall survival between patients on and not on acid suppression therapy.

“Capecitabine is an oral chemotherapeutic agent used in colorectal cancer,” the investigators said. “Two prior studies found a negative impact with the concomitant use of proton pump inhibitor agents during treatment with capecitabine in patients with early colorectal and gastroesophageal cancers.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.
Roshini Claire Anthony, 5 days ago

Female cancer survivors who undergo fertility preservation before cancer treatment often use their stored gametes/embryos. This highlights the effectiveness of pre-cancer fertility preservation, according to a study presented at ESHRE 2020.